

Bioservo - Prepped for commercialization going into 2023

Redeye saw no breakthrough in sales in Q4, and costs were higher than expected. During Q4, there has been some positive development. The financial situation has improved with the share issue, Carbonhand has been MDR approved, and the iHand study was very positive. Cost reductions have been implemented that will come into effect during 2023e. We both lower and increase our estimates and change the number of shares. The estimate changes and some balance sheet maintenance alter our Base Case to SEK 5 (6) per share. We still see a compelling long-term case, and the Carbonhand commercialization has the potential to surprise.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Bioservo - Prepped for commercialization going into 2023